These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 35671327)

  • 1. Radiotherapy to the prostate for men with metastatic prostate cancer in the UK and Switzerland: Long-term results from the STAMPEDE randomised controlled trial.
    Parker CC; James ND; Brawley CD; Clarke NW; Ali A; Amos CL; Attard G; Chowdhury S; Cook A; Cross W; Dearnaley DP; Douis H; Gilbert DC; Gilson C; Gillessen S; Hoyle A; Jones RJ; Langley RE; Malik ZI; Mason MD; Matheson D; Millman R; Rauchenberger M; Rush H; Russell JM; Sweeney H; Bahl A; Birtle A; Capaldi L; Din O; Ford D; Gale J; Henry A; Hoskin P; Kagzi M; Lydon A; O'Sullivan JM; Paisey SA; Parikh O; Pudney D; Ramani V; Robson P; Srihari NN; Tanguay J; Parmar MKB; Sydes MR;
    PLoS Med; 2022 Jun; 19(6):e1003998. PubMed ID: 35671327
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial.
    Parker CC; James ND; Brawley CD; Clarke NW; Hoyle AP; Ali A; Ritchie AWS; Attard G; Chowdhury S; Cross W; Dearnaley DP; Gillessen S; Gilson C; Jones RJ; Langley RE; Malik ZI; Mason MD; Matheson D; Millman R; Russell JM; Thalmann GN; Amos CL; Alonzi R; Bahl A; Birtle A; Din O; Douis H; Eswar C; Gale J; Gannon MR; Jonnada S; Khaksar S; Lester JF; O'Sullivan JM; Parikh OA; Pedley ID; Pudney DM; Sheehan DJ; Srihari NN; Tran ATH; Parmar MKB; Sydes MR;
    Lancet; 2018 Dec; 392(10162):2353-2366. PubMed ID: 30355464
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial.
    James ND; Sydes MR; Clarke NW; Mason MD; Dearnaley DP; Spears MR; Ritchie AW; Parker CC; Russell JM; Attard G; de Bono J; Cross W; Jones RJ; Thalmann G; Amos C; Matheson D; Millman R; Alzouebi M; Beesley S; Birtle AJ; Brock S; Cathomas R; Chakraborti P; Chowdhury S; Cook A; Elliott T; Gale J; Gibbs S; Graham JD; Hetherington J; Hughes R; Laing R; McKinna F; McLaren DB; O'Sullivan JM; Parikh O; Peedell C; Protheroe A; Robinson AJ; Srihari N; Srinivasan R; Staffurth J; Sundar S; Tolan S; Tsang D; Wagstaff J; Parmar MK;
    Lancet; 2016 Mar; 387(10024):1163-77. PubMed ID: 26719232
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol.
    Sydes MR; Spears MR; Mason MD; Clarke NW; Dearnaley DP; de Bono JS; Attard G; Chowdhury S; Cross W; Gillessen S; Malik ZI; Jones R; Parker CC; Ritchie AWS; Russell JM; Millman R; Matheson D; Amos C; Gilson C; Birtle A; Brock S; Capaldi L; Chakraborti P; Choudhury A; Evans L; Ford D; Gale J; Gibbs S; Gilbert DC; Hughes R; McLaren D; Lester JF; Nikapota A; O'Sullivan J; Parikh O; Peedell C; Protheroe A; Rudman SM; Shaffer R; Sheehan D; Simms M; Srihari N; Strebel R; Sundar S; Tolan S; Tsang D; Varughese M; Wagstaff J; Parmar MKB; James ND;
    Ann Oncol; 2018 May; 29(5):1235-1248. PubMed ID: 29529169
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of Bone Metastatic Burden With Survival Benefit From Prostate Radiotherapy in Patients With Newly Diagnosed Metastatic Prostate Cancer: A Secondary Analysis of a Randomized Clinical Trial.
    Ali A; Hoyle A; Haran ÁM; Brawley CD; Cook A; Amos C; Calvert J; Douis H; Mason MD; Dearnaley D; Attard G; Gillessen S; Parmar MKB; Parker CC; Sydes MR; James ND; Clarke NW
    JAMA Oncol; 2021 Apr; 7(4):555-563. PubMed ID: 33599706
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial.
    Clarke NW; Ali A; Ingleby FC; Hoyle A; Amos CL; Attard G; Brawley CD; Calvert J; Chowdhury S; Cook A; Cross W; Dearnaley DP; Douis H; Gilbert D; Gillessen S; Jones RJ; Langley RE; MacNair A; Malik Z; Mason MD; Matheson D; Millman R; Parker CC; Ritchie AWS; Rush H; Russell JM; Brown J; Beesley S; Birtle A; Capaldi L; Gale J; Gibbs S; Lydon A; Nikapota A; Omlin A; O'Sullivan JM; Parikh O; Protheroe A; Rudman S; Srihari NN; Simms M; Tanguay JS; Tolan S; Wagstaff J; Wallace J; Wylie J; Zarkar A; Sydes MR; Parmar MKB; James ND
    Ann Oncol; 2019 Dec; 30(12):1992-2003. PubMed ID: 31560068
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Automated Bone Scan Index as a Predictor of Response to Prostate Radiotherapy in Men with Newly Diagnosed Metastatic Prostate Cancer: An Exploratory Analysis of STAMPEDE's "M1|RT Comparison".
    Ali A; Hoyle AP; Parker CC; Brawley CD; Cook A; Amos C; Calvert J; Douis H; Mason MD; Attard G; Parmar MKB; Sydes MR; James ND; Clarke NW;
    Eur Urol Oncol; 2020 Aug; 3(4):412-419. PubMed ID: 32591246
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Docetaxel for Nonmetastatic Prostate Cancer: Long-Term Survival Outcomes in the STAMPEDE Randomized Controlled Trial.
    James ND; Ingleby FC; Clarke NW; Amos CL; Attard G; Brawley CD; Chowdhury S; Cross W; Dearnaley DP; Gilbert DC; Gillessen S; Jones RJ; Langley RE; Macnair A; Malik ZI; Mason MD; Matheson DJ; Millman R; Parker CC; Rush HL; Russell JM; Au C; Ritchie AWS; Mestre RP; Ahmed I; Birtle AJ; Brock SJ; Das P; Ford VA; Gray EK; Hughes RJ; Manetta CB; McLaren DB; Nikapota AD; O'Sullivan JM; Perna C; Peedell C; Protheroe AS; Sundar S; Tanguay JS; Tolan SP; Wagstaff J; Wallace JB; Wylie JP; Zarkar A; Parmar MKB; Sydes MR
    JNCI Cancer Spectr; 2022 Jul; 6(4):. PubMed ID: 35877084
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5-year follow-up results from the STAMPEDE randomised trial (NCT00268476).
    James ND; Clarke NW; Cook A; Ali A; Hoyle AP; Attard G; Brawley CD; Chowdhury S; Cross WR; Dearnaley DP; de Bono JS; Diaz-Montana C; Gilbert D; Gillessen S; Gilson C; Jones RJ; Langley RE; Malik ZI; Matheson DJ; Millman R; Parker CC; Pugh C; Rush H; Russell JM; Berthold DR; Buckner ML; Mason MD; Ritchie AWS; Birtle AJ; Brock SJ; Das P; Ford D; Gale J; Grant W; Gray EK; Hoskin P; Khan MM; Manetta C; McPhail NJ; O'Sullivan JM; Parikh O; Perna C; Pezaro CJ; Protheroe AS; Robinson AJ; Rudman SM; Sheehan DJ; Srihari NN; Syndikus I; Tanguay JS; Thomas CW; Vengalil S; Wagstaff J; Wylie JP; Parmar MKB; Sydes MR;
    Int J Cancer; 2022 Aug; 151(3):422-434. PubMed ID: 35411939
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Failure-Free Survival and Radiotherapy in Patients With Newly Diagnosed Nonmetastatic Prostate Cancer: Data From Patients in the Control Arm of the STAMPEDE Trial.
    James ND; Spears MR; Clarke NW; Dearnaley DP; Mason MD; Parker CC; Ritchie AW; Russell JM; Schiavone F; Attard G; de Bono JS; Birtle A; Engeler DS; Elliott T; Matheson D; O'Sullivan J; Pudney D; Srihari N; Wallace J; Barber J; Syndikus I; Parmar MK; Sydes MR;
    JAMA Oncol; 2016 Mar; 2(3):348-57. PubMed ID: 26606329
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quality of Life in Men With Prostate Cancer Randomly Allocated to Receive Docetaxel or Abiraterone in the STAMPEDE Trial.
    Rush HL; Murphy L; Morgans AK; Clarke NW; Cook AD; Attard G; Macnair A; Dearnaley DP; Parker CC; Russell JM; Gillessen S; Matheson D; Millman R; Brawley CD; Pugh C; Tanguay JS; Jones RJ; Wagstaff J; Rudman S; O'Sullivan JM; Gale J; Birtle A; Protheroe A; Gray E; Perna C; Tolan S; McPhail N; Malik ZI; Vengalil S; Fackrell D; Hoskin P; Sydes MR; Chowdhury S; Gilbert DC; Parmar MKB; James ND; Langley RE
    J Clin Oncol; 2022 Mar; 40(8):825-836. PubMed ID: 34757812
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer (HYPO-RT-PC): patient-reported quality-of-life outcomes of a randomised, controlled, non-inferiority, phase 3 trial.
    Fransson P; Nilsson P; Gunnlaugsson A; Beckman L; Tavelin B; Norman D; Thellenberg-Karlsson C; Hoyer M; Lagerlund M; Kindblom J; Ginman C; Johansson B; Björnlinger K; Seke M; Agrup M; Zackrisson B; Kjellén E; Franzén L; Widmark A
    Lancet Oncol; 2021 Feb; 22(2):235-245. PubMed ID: 33444529
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: first results from the STAMPEDE multiarm, multistage, randomised controlled trial.
    James ND; Sydes MR; Mason MD; Clarke NW; Anderson J; Dearnaley DP; Dwyer J; Jovic G; Ritchie AW; Russell JM; Sanders K; Thalmann GN; Bertelli G; Birtle AJ; O'Sullivan JM; Protheroe A; Sheehan D; Srihari N; Parmar MK;
    Lancet Oncol; 2012 May; 13(5):549-58. PubMed ID: 22452894
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adding Celecoxib With or Without Zoledronic Acid for Hormone-Naïve Prostate Cancer: Long-Term Survival Results From an Adaptive, Multiarm, Multistage, Platform, Randomized Controlled Trial.
    Mason MD; Clarke NW; James ND; Dearnaley DP; Spears MR; Ritchie AWS; Attard G; Cross W; Jones RJ; Parker CC; Russell JM; Thalmann GN; Schiavone F; Cassoly E; Matheson D; Millman R; Rentsch CA; Barber J; Gilson C; Ibrahim A; Logue J; Lydon A; Nikapota AD; O'Sullivan JM; Porfiri E; Protheroe A; Srihari NN; Tsang D; Wagstaff J; Wallace J; Walmsley C; Parmar MKB; Sydes MR;
    J Clin Oncol; 2017 May; 35(14):1530-1541. PubMed ID: 28300506
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Addition of Docetaxel to First-line Long-term Hormone Therapy in Prostate Cancer (STAMPEDE): Modelling to Estimate Long-term Survival, Quality-adjusted Survival, and Cost-effectiveness.
    Woods BS; Sideris E; Sydes MR; Gannon MR; Parmar MKB; Alzouebi M; Attard G; Birtle AJ; Brock S; Cathomas R; Chakraborti PR; Cook A; Cross WR; Dearnaley DP; Gale J; Gibbs S; Graham JD; Hughes R; Jones RJ; Laing R; Mason MD; Matheson D; McLaren DB; Millman R; O'Sullivan JM; Parikh O; Parker CC; Peedell C; Protheroe A; Ritchie AWS; Robinson A; Russell JM; Simms MS; Srihari NN; Srinivasan R; Staffurth JN; Sundar S; Thalmann GN; Tolan S; Tran ATH; Tsang D; Wagstaff J; James ND; Sculpher MJ
    Eur Urol Oncol; 2018 Dec; 1(6):449-458. PubMed ID: 31158087
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): 10-year results from a randomised, phase 3, factorial trial.
    Denham JW; Joseph D; Lamb DS; Spry NA; Duchesne G; Matthews J; Atkinson C; Tai KH; Christie D; Kenny L; Turner S; Gogna NK; Diamond T; Delahunt B; Oldmeadow C; Attia J; Steigler A
    Lancet Oncol; 2019 Feb; 20(2):267-281. PubMed ID: 30579763
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Survival with Newly Diagnosed Metastatic Prostate Cancer in the "Docetaxel Era": Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019).
    James ND; Spears MR; Clarke NW; Dearnaley DP; De Bono JS; Gale J; Hetherington J; Hoskin PJ; Jones RJ; Laing R; Lester JF; McLaren D; Parker CC; Parmar MKB; Ritchie AWS; Russell JM; Strebel RT; Thalmann GN; Mason MD; Sydes MR
    Eur Urol; 2015 Jun; 67(6):1028-1038. PubMed ID: 25301760
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design.
    Fizazi K; Foulon S; Carles J; Roubaud G; McDermott R; Fléchon A; Tombal B; Supiot S; Berthold D; Ronchin P; Kacso G; Gravis G; Calabro F; Berdah JF; Hasbini A; Silva M; Thiery-Vuillemin A; Latorzeff I; Mourey L; Laguerre B; Abadie-Lacourtoisie S; Martin E; El Kouri C; Escande A; Rosello A; Magne N; Schlurmann F; Priou F; Chand-Fouche ME; Freixa SV; Jamaluddin M; Rieger I; Bossi A;
    Lancet; 2022 Apr; 399(10336):1695-1707. PubMed ID: 35405085
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TRAPEZE: a randomised controlled trial of the clinical effectiveness and cost-effectiveness of chemotherapy with zoledronic acid, strontium-89, or both, in men with bony metastatic castration-refractory prostate cancer.
    James N; Pirrie S; Pope A; Barton D; Andronis L; Goranitis I; Collins S; McLaren D; O'Sullivan J; Parker C; Porfiri E; Staffurth J; Stanley A; Wylie J; Beesley S; Birtle A; Brown J; Chakraborti P; Russell M; Billingham L
    Health Technol Assess; 2016 Jul; 20(53):1-288. PubMed ID: 27434595
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of newly diagnosed glioblastoma in the elderly: a network meta-analysis.
    Hanna C; Lawrie TA; Rogozińska E; Kernohan A; Jefferies S; Bulbeck H; Ali UM; Robinson T; Grant R
    Cochrane Database Syst Rev; 2020 Mar; 3(3):CD013261. PubMed ID: 32202316
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.